Skip to content
DataLookout
Menu

ACSNCT07102628

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Trial sites reduced: 69 → 65 locations
    • Enrollment target: estimated 300 to confirmed 305
    • Primary and study completion dates: Feb 11, 2027 to Jan 16, 2027
  2. Notable Eligibility criteria expanded, about 71 words
    • Secondary endpoints: details revised at 4 of 10 entries
    • Study description expanded, about 5 words
  3. Minor Study sites: 68 to 69v11
  4. Minor Trial sites expanded: 63 → 68 locationsv10
  5. Minor Trial sites expanded: 60 → 63 locationsv9
  6. Minor Study sites: 58 to 60v8
  7. Minor Trial sites expanded: 52 → 58 locations
    • Primary and study completion dates: Feb 15, 2027 to Feb 11, 2027
    v7
  8. Minor Trial sites expanded: 26 → 52 locationsv6
  9. Minor Study sites: 15 to 26v5
  10. Minor Study sites: 9 to 15v4
  11. Minor Study sites: 2 to 9v3
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Primary and study completion dates: Mar 6, 2027 to Feb 15, 2027
    • Start date changed from estimate of Sep 30, 2025 to Oct 3, 2025
    v2
  13. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percent change in LDL-C
Timeframe: From baseline to Day 150

Secondary (10)

Participants achieving LDL-C <70 mg/dL (yes, no)
Participants achieving LDL-C <55 mg/dL (yes, no)
Participants achieving LDL-C <100 mg/dL (yes, no) (among the subset of participants with LDL-C ≥100 mg/dL at baseline)
Participants achieving ≥50% reduction from baseline in LDL-C (yes, no)
Percent change from baseline to mean LDL-C over the double-blind treatment period (averaged over all post-baseline visits)
Show 5 moreShow less
Absolute change from baseline to mean LDL-C over the double-blind treatment period (averaged over all post-baseline visits)
Percent change in LDL-C
Absolute change in LDL-C
Percent change and absolute change in PCSK9
Percent change and absolute change from baseline in: apoB, VLDL, non-HDLC, HDL-C, total cholesterol and triglycerides

Arms and interventions

Inclisiran sodium 300 mg s.c. + Standard treatmentExperimental

* Inclisiran sodium 300 mg subcutaneous (s.c.) on top of HIS (+/- LLT) or non-statin LLT in statin intolerant participants * KJX839 284 mg / 1.5 mL (Dose: 300 mg) * Pharmaceutical Dosage Form: solution for subcutaneous injection

Matching placebo + Standard treatmentPlacebo comparator

* Matching placebo on top of HIS (+/- LLT) or non-statin LLT in statin intolerant participants * KJX839 Placebo / 1.5 mL (Dose: 0 mg) * Pharmaceutical Dosage Form: solution for subcutaneous injection

Drugs: Placebo, Inclisiran

Sites

65 sites in 13 countries

China 15, Spain 9, Germany 6, France 5, Hungary 5, Canada 4, India 4, Japan 4, Poland 4, Switzerland 3, Australia 2, Hong Kong 2, South Korea 2